• Swiss drugmaker Novartis' investigational drug Tasigna helped more than 90 percent of patients diagnosed with an unresponsive form of leukemia, according to a clinical trial published in the New England Journal of Medicine. (fdanews.com)
  • 001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. (bloodjournal.org)
  • The PACE trial is a global, single-arm clinical study of oral ponatinib in 320 patients with chronic phase, accelerated phase, or blast phase CML, as well as Ph+ ALL. (empr.com)
  • The discovery of genetic alterations associated with tumor growth and therapeutic response is critical to the development of effective cancer therapeutics. (aacrjournals.org)
  • It was first approved for adult CML patients with any phase disease who had failed or were intolerant to prior therapy, including Gleevec, in the US and 5EU in 2006, and Japan in 2009. (gii.co.jp)
  • Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. (springer.com)
  • Cisplatin seems to be a better option than gemcitabine when used concurrently with radiation for locally advanced cervical cancer both in terms of response and toxicity. (ijmpo.org)
  • In this study, we investigated the effects of ATO and nilotinib on the proliferation and differentiation of CML-BC cells isolated from CML patients in the BC phase. (biomedcentral.com)
  • Following Prostate Cancer Working Group 2 guidelines, lack of progression according to Response Evaluation Criteria in Solid Tumor and bone scan was determined and reported at 12 and 24 weeks. (aacrjournals.org)
  • Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. (gii.co.jp)